Pharmacokinetics of intravenous methotrexate in mutant Nagase analbuminemic rats

被引:15
作者
Choi, Young H.
Bae, Soo K.
Oh, Jung M.
Sun-Ok, Kim
Lee, Myung G.
机构
[1] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[2] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 151742, South Korea
[3] Samyang Cent R&D Ctr, Taejon, South Korea
关键词
methotrexate; NARs; pharmacokinetics; glomerular filtration; rats;
D O I
10.1002/bdd.565
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It has been reported that the plasma (or serum) levels of albumin and globulins were lower and higher, respectively, than the serum levels in control rats. Hence, it could be expected that these changes could affect the renal clearance (Cl-r) of methotrexate in Nagase analbuminemic rats (NARs) due to changes in plasma protein binding values. Therefore, methotrexate at a dose of 100mg/kg was administered intravenously to control rats and NARs. The plasma protein binding of methotrexate in NARs was significantly greater (29.4% increase) than the controls, probably due to the considerable binding of the drug (34.2%) to 1.8% beta-plus 0.63% gamma-globulins. The Or of methotrexate in NARs was significantly slower (36.1% decrease) than the controls, due to the significantly smaller Ae(0-24) h (25.8% decrease). The smaller Ae(0-24) h could be due to the significantly smaller free (unbound to plasma proteins) fractions of methotrexate in plasma (13.8% decrease) in NARs, since methotrexate was mainly excreted in the urine via glomerular filtration. However, the Cl-nr values were comparable between the control rats and NARs. This could be because methotrexate is not metabolized considerably via hepatic CYP isozymes based on control rats pretreated with SKF 525-A (a nonspecific inhibitor of hepatic CYP isozymes in rats). Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:385 / 392
页数:8
相关论文
共 35 条
[1]   Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer [J].
Al Murri, AM ;
Bartlett, JMS ;
Canney, PA ;
Doughty, JC ;
Wilson, C ;
McMillan, DC .
BRITISH JOURNAL OF CANCER, 2006, 94 (02) :227-230
[2]   Pharmacokinetics of oltipraz in mutant Nagase analbuminemic rats [J].
Bae, SK ;
Kang, HE ;
Kang, MK ;
Kim, JW ;
Kim, T ;
Lee, MG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (05) :998-1005
[3]  
BISTRIAN BR, 1986, CANCER-AM CANCER SOC, V58, P1863, DOI 10.1002/1097-0142(19861015)58:8+<1863::AID-CNCR2820581412>3.0.CO
[4]  
2-P
[5]  
BREMNES RM, 1989, CANCER RES, V49, P6359
[6]  
Chabner BA, 2006, GOODMAN GILMANS PHAR, P1335
[7]   SENSITIVE AND RAPID HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS DETERMINATION OF METHOTREXATE AND ITS METABOLITES IN PLASMA, SALIVA AND URINE [J].
CHEN, ML ;
CHIOU, WL .
JOURNAL OF CHROMATOGRAPHY, 1981, 226 (01) :125-134
[8]   NEW CALCULATION METHOD OF MEAN TOTAL-BODY CLEARANCE OF DRUGS AND ITS APPLICATION TO DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (01) :90-91
[9]   NEW CALCULATION METHOD FOR MEAN APPARENT DRUG VOLUME OF DISTRIBUTION AND APPLICATION TO RATIONAL DOSAGE REGIMENS [J].
CHIOU, WL .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (08) :1067-1069
[10]   CRITICAL EVALUATION OF THE POTENTIAL ERROR IN PHARMACOKINETIC STUDIES OF USING THE LINEAR TRAPEZOIDAL RULE METHOD FOR THE CALCULATION OF THE AREA UNDER THE PLASMA LEVEL TIME CURVE [J].
CHIOU, WL .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1978, 6 (06) :539-546